Correction to: Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor
Pulm Ther
.
2020 Dec;6(2):287.
doi: 10.1007/s41030-020-00128-3.
Authors
Alice Tsai
1
,
Shu-Pei Wu
2
,
Eric Haseltine
2
,
Sanjeev Kumar
2
,
Samuel M Moskowitz
2
,
Paul Panorchan
2
,
Kushal Shah
2
Affiliations
1
Vertex Pharmaceuticals Incorporated, Boston, MA, USA. alice_tsai@vrtx.com.
2
Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
PMID:
32856286
PMCID:
PMC7672129
DOI:
10.1007/s41030-020-00128-3
Abstract
The original version of this article unfortunately contained a mistake.
Publication types
Published Erratum